Synergistics technologies

The three Faron's drug target molecules, two enzymes (AOC3/SSAO and CD73/5’-nucleotidase) and one adhesion receptor (CLEVER-1), are all expressed, either to endothelial cell surfaces of blood or lymphatic vessels, or to both. They can also be present in body fluids, such as plasma. They also share same disease indications, many development technologies and disease models, providing strong synergy between projects and lowering project development costs.